Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.

Abstract

Twenty-six patients with advanced cancer of the prostate were treated with [D-SER(BUt)6]LHRH-(1-9) nonapeptide ethylamide (buserelin). All but 6 patients evidenced signs of metastasis. Blood prolactin levels were measured prior to the initiation of treatment and during a follow-up period of 18 months. A statistically significant (p greater than 0.0005) elevation in serum prolactin levels was observed after 3 months of treatment. Serum prolactin remained elevated for a total of 6 months, after which a decline to pretreatment levels was observed. Our observation of a transient rise in prolactin levels during the chronic administration of buserelin is at variance with previously published data which reported unchanged prolactin levels during such treatment.

• Authors: Y I Siegel, D Korczak, A Lindner
• Journal: European urology (Eur Urol) Vol. 19 Issue 1 Pg. 16-8 ( 1991) ISSN: 0302-2838 [Print] Switzerland
• PMID: 1901042 (Publication Type: Journal Article)

Chemical References

• Prolactin
• Buserelin

Topics

• Adenocarcinoma (blood, drug therapy)
• Aged
• Buserelin (therapeutic use)
• Follow-Up Studies
• Humans
• Male
• Prolactin (blood)
• Prostatic Neoplasms (blood, drug therapy)
• Time Factors